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Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S306patients. NM conditioning consisted of ﬂudarabine 90mg/m2
plus 2 Gy TBI, while MA conditioning was cyclophosphamide
120 mg/m2 in combination with 12 Gy TBI or 12.8 mg/kg
busilvex. MA conditioning was given to 122 patients and NM
to 85 patients. Median age at transplant was 39 (range 15-56)
in MA patients and 59 (range 27-73) in NM patients. Donor
source, cytogenetic risk, CMV antigen status recipient/donor,
sex match, Karnofsky score, and body mass index were not
different among MA and NM patients. Disease stages CR1,
CR2, and >CR2/Primary Induction Failure (PIF) were
analyzed separately. Survival of patients with advanced stage
(>CR2/PIF) was short in both groups; 6.1 and 5.2 months in
MA and NM, respectively. Patients in CR1 and CR2 were
analyzed in details. Patient numbers in MA and NM trans-
plants were 60 vs. 62 in CR1 and 50 vs. 17 in CR2. In CR1 and
CR2 MA patients 68% and 48% received bone marrow,
whereas all of the NM patients received peripheral stem
cells, P < .001. Day 100 TRM in MA vs. NM transplants was
8.3% vs. 1.6% in CR1patients and 14% vs. 5.9% in CR2 patients,
which was not signiﬁcantly different. Relapse incidence was
comparable among the MA and NM transplants, both in CR1
and CR2 patients. The cumulative incidence of relapse at 1
year was 18.4% (CI: 5.0-28.2) versus 20.9% (CI: 5.2-31.1) inMA
and NM patients transplanted in CR1, and 14.5% (CI: 5.1-24.5)
versus 11.8% (CI: 0- 27.1) in CR2 patients (n.s.). The 5 year
overall survival (OS) probability in the CR1 patients with MA
conditioning vs NM conditioning was 63.9% (CI:51.4-76.4) vs
64.0% (CI:51.4-76.6), and among CR2 patients 51.2% (CI:36.0-
66.4) vs 64.7 (CI:41.9-87.4), (n.s.). The median survival
follow-up time was 55 months (range: 9-137) among CR 1
patients, and 54 months (range: 7-133) among CR2 patients.
The 3-year cumulative incidence of chronic GVHD in CR1
patients was 52.8% (CI:39.9-65.8) and 41.9% (CI:29.3-54.7) in
MA and NM patients, respectively. In CR2 patients, the inci-
dences were 32.7% (CI:19.0-46.3) and 41.2% (CI:17.8-64.6). In
conclusion, OS, TRM and relapse in NM transplants were
comparable to MA transplants despite a truly NM regimen
and a substantial age difference between groups.Figure 1. OS by Second HCT for Patients with Post-HCT Relapse394
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Background: Relapse is the primary cause of treatment
failure after alloHCT for hematologic malignancies. We
describe the presentation, management, and outcomes of
childrenwith post-HCT relapse, speciﬁcally focusing on post-
HCT minimal residual disease (MRD), to improve monitoring
and intervention strategies.
Design: This was a single institution, retrospective cohort
study of children with relapse or progression of acute
lymphoblastic leukemia (ALL), acute myelogenous leukemia
(AML), mixed phenotypic acute leukemia (MPAL) or myelo-
dysplastic syndrome (MDS) post-alloHCT between January 1,
2003 and December 31, 2010. MRD was deﬁned as disease
detectable by immunophenotypic, cytogenetic or molecular
methods that did not meet classic morphologic criteria for
relapse (deﬁned as 5% disease). Relapse was deﬁned as any
evidence for disease detected after previously negativeresults, includingMRD. Progressive diseasewas deﬁned as an
increase in any measure from baseline results.
Results: 40 of 93 (43%) patients who underwent a ﬁrst
alloHCT experienced relapse, including patients with AML
(n¼18), ALL (n¼16), MPAL (n¼4) andMDS (n¼2). Themedian
time from alloHCT to relapse was 144 days (range 1 month-
58 months). Nine patients with post-HCT MRD as the ﬁrst
evidence for relapse, presented at a median time of 35 days
post-HCT (range 28-182 days), with the majority having
rapid progression of disease. Median survival after relapse
was 123 days (range 4 days-5 years). Estimated 6-month and
1-year post-relapse survival was 30% and 17.5%, respectively.
Five of 40 (12.5%) patients are currently alive with a median
follow-up of 39 months, including 1 patient with active
disease. 1 survivor had MDS and presented with MRD alone.
The remaining 4 (with leukemia) presented with overt
disease between 146 and 411 days post-HCT. 3 of 5 survivors
underwent a second HCT. 11 patients who were able to
undergo a second transplant, experienced a 3-year 27% OS
starting after relapse. (Figure 1). No patients with AML
survived after relapse.
Conclusion: Although pre-emptive treatment of relapse in
the setting of MRD is felt to be ideal, it may not be feasible. In
our study, patients with MRD presented very early post-HCT
at a time when complications can be high and therapeutic
options are limited. Once MRD was detected, disease
progression was rapid limiting the chance to respond to
frontline immunotherapeutic options. Accordingly, there
was no survival advantage for pediatric patients with
leukemia whose relapse was detected as MRD compared to
overt disease. Given the poor outcomes of post-HCT relapse
and limited ability to treat relapse at the stage ofMRD, efforts
should focus on developing effective therapies for relapse
prevention by identifying those at highest risk of relapse as
candidates for novel methods to enhance efﬁcacy of alloHCT.395
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